Latest revenue
$90.0K
as of 2025-09-30
Latest net income
$-5.1M
as of 2025-09-30
Net margin
-5701.1%
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ATNM is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for ATNM.
5-year trend
What this company does
Item 1. Business. Business Overview Actinium Pharmaceuticals, Inc. is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and deep understanding of radiobiology to the development of novel targeted therapies known as Antibody Radiation-Conjugates (“ARCs”). Radiation is an effective therapeutic modality that is used in the treatment of over fifty percent of all cancer patients and is often combined with chemotherapy, immunotherapy and other treatments for greater therapeutic effect. Radiation is typically administered via an external beam source from outside the body, leading to off-target exposure to normal healthy tissue and organs, which can constrain…
AI summary unavailable — showing raw filing excerpt
Generated from ATNM's filing dated 2021-03-31
Key risks
ITEM 1A. RISK FACTORS In analyzing our company, you should consider carefully the following risk factors, together with all of the other information included in this Annual Report on Form 10-K. Factors that could cause or contribute to differences in our actual results include those discussed in the following subsection, as well as those discussed above in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere throughout this Annual Report on Form 10-K. Each of the following risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an…
AI summary unavailable — showing raw filing excerpt
Generated from ATNM's filing dated 2021-03-31
Profitability
Operating margin
-1535.9%
41.4%Net margin
-1435.9%
45.6%Return on equity
-432.6%
270.5%Return on assets
-65.5%
31.6%Leverage
Debt / equity
5.61×
316.3%Long-term debt / equity
0.00×
3.9%Debt / assets
84.9%
47.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-5.5M | +65.4% | — |
Q4 2025 2025-12-31 | — | — | $-5.9M | +10.7% | — |
Q3 2025 2025-09-30 | $90.0K | — | $-5.1M | +55.6% | -5701.1% |
Q2 2025 2025-06-30 | — | — | $-6.9M | +39.4% | — |
Q1 2025 2025-03-31 | — | — | $-15.9M | -83.8% | — |
Q4 2024 2024-12-31 | — | — | $-6.7M | — | — |
Q3 2024 2024-09-30 | — | — | $-11.6M | +12.9% | — |
Q2 2024 2024-06-30 | — | — | $-11.4M | +25.2% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ATNM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATNM
Institutional value
$2.4M
Total shares held
3.0M
Distinct holders
31
-28 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $1.2M | — | New |
| 2 | BlackRock, Inc. | 371.2K | $369.5K | +4.3K (+1.2%) | Added |
| 3 | GAGNON SECURITIES LLC | 201.3K | $200.4K | -507 (-0.3%) | Trimmed |
| 4 | VANGUARD FIDUCIARY TRUST CO | 160.3K | $159.5K | — | New |
| 5 | Gen-Wealth Partners Inc | 107.1K | $106.6K | -20 (-0.0%) | Trimmed |
| 6 | Gerald Baker Financial Group LLC | 45.4K | $51.2K | — | New |
| 7 | NINE MASTS CAPITAL Ltd | 35.2K | $35.1K | +22.3K (+172.2%) | Added |
| 8 | DIMENSIONAL FUND ADVISORS LP | 34.9K | $34.8K | +0 (+0.0%) | No change |
| 9 | JANE STREET GROUP, LLC | 34.3K | $34.1K | -58.9K (-63.2%) | Trimmed |
| 10 | Vontobel Holding Ltd. | 30.0K | $29.9K | +0 (+0.0%) | No change |
| 11 | MAYPORT, LLC | 22.0K | $21.9K | +0 (+0.0%) | No change |
| 12 | NORTH STAR ASSET MANAGEMENT INC | 20.0K | $19.9K | +0 (+0.0%) | No change |
| 13 | WELLS FARGO & COMPANY/MN | 19.8K | $19.7K | +0 (+0.0%) | No change |
| 14 | UBS Group AG | 14.6K | $14.5K | +14.5K (+15127.1%) | Added |
| 15 | Callan Family Office, LLC | 11.9K | $11.9K | -11.7K (-49.4%) | Trimmed |
| 16 | Intrepid Financial Planning Group LLC | 10.5K | $10.5K | +0 (+0.0%) | No change |
| 17 | Savvy Advisors, Inc. | 10.0K | $10.0K | +0 (+0.0%) | No change |
| 18 | Vanguard Global Advisers, LLC | 8.9K | $8.8K | — | New |
| 19 | Steward Partners Investment Advisory, LLC | 2.2K | $2.2K | +0 (+0.0%) | No change |
| 20 | JPMORGAN CHASE & CO | 1.5K | $1.5K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATNM's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.